{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:32Z","timestamp":1793298932125,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["834974"],"award-info":[{"award-number":["834974"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010124","name":"Erich und Gertrud Roggenbuck Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2025.10.006","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:46:40Z","timestamp":1772228800000},"page":"900-906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography\u2013positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial"],"prefix":"10.1016","volume":"12","author":[{"given":"Sabine","family":"Riethdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Knipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Coith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.10.006_b0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, Predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0015","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2025.10.006_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.euf.2025.10.006_b0025","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Mottet","year":"2023"},{"key":"10.1016\/j.euf.2025.10.006_b0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2025.10.006_b0040","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.euf.2018.02.015","article-title":"Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study","volume":"5","author":"Steuber","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.10.006_b0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.10.006_b0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort Study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.euf.2025.10.006_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12885-017-3341-2","article-title":"Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)","volume":"22","author":"Habl","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2025.10.006_b0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1373\/clinchem.2018.287102","article-title":"Circulating tumor cells in prostate cancer: from discovery to clinical utility","volume":"65","author":"Pantel","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.euf.2025.10.006_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2025.10.006_b0075","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pros.24787","article-title":"Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy","volume":"84","author":"Matrone","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.10.006_b0080","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s11255-023-03622-0","article-title":"Perioperative change of circulating tumor cells in cytoreductive radical prostatectomy for oligometastatic hormone-sensitive prostate cancer: the preliminary safety evidence from long-term oncologic outcomes","volume":"55","author":"Maskey","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2025.10.006_b0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euf.2019.05.008","article-title":"Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer\u2014translational research results from the prospective ProMPT trial","volume":"7","author":"Mandel","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.10.006_b0090","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.10.006_b0095","doi-asserted-by":"crossref","first-page":"235.e11","DOI":"10.1016\/j.urolonc.2015.12.003","article-title":"Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.10.006_b0100","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.juro.2008.01.102","article-title":"Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer","volume":"179","author":"Davis","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2018.12.004","article-title":"The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper","volume":"134","author":"Cristofanilli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euf.2025.10.006_b0110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1373\/clinchem.2017.281295","article-title":"In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in circulating tumor cells","volume":"64","author":"El-Heliebi","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.euf.2025.10.006_b0115","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eururo.2024.11.011","article-title":"Novel methods to assess tumor burden and minimal residual disease in genitourinary cancers","volume":"87","author":"Barata","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.10.006_b0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.23.00456","article-title":"Overall survival with circulating tumor cell count-driven choice of therapy in advanced breast cancer: a randomized trial","volume":"42","author":"Bidard","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:59:29Z","timestamp":1793296769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456925002925"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.10.006","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography\u2013positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}